Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-PMF phase 3 study of ropeginterferon alfa-2b in low-risk or intermediate-1-risk primary myelofibrosis
CTR20251786Phase 3Active
- Sponsor
- PharmaEssentia
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ropeginterferon alfa-2b in primary myelofibrosis (PMF), sponsored by PharmaEssentia. Started Oct 2025; status: active.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on CTR20251786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251786.